Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature

7Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: To evaluate the initial experience and clinical utility of first-line adjuvant intensity-modulated whole abdominal radiation therapy (WART) in women with ovarian clear cell cancer (OCCC) referred to an academic center. Methods: Progression-free and overall survival was analyzed in a pragmatic observational cohort study of histologically pure OCCC patients over-expressing HNF-1ß treated between 2013 and end-December 2018. An in-house intensity-modulated WART program was developed from a published pre-clinical model. Radiation dose-volume data was curated to American Association of Physics in Medicine (AAPM) Task Group 263 recommendations. A dedicated database prospectively recorded presenting characteristics and outcomes in a standardized fashion. Results: Five women with FIGO (2018) stage IA to IIIA2 OCCC were treated with first-line WART. Median age was 58 years (range 47–68 years). At diagnosis CA-125 was elevated in 4 cases (median 56 kU/L: range 18.4–370 kU/L) before primary de-bulking surgery. Severe premorbid endometriosis was documented in 3 patients. At a median follow-up of 77 months (range 16–83 mo.), all patients remain alive and progression-free on clinical, biochemical (CA-125), and 18Fluoro-deoxyglucose (FDG) PET/CT re-evaluation. Late radiation toxicity was significant (G3) in 1 case who required a limited bowel resection and chronic nutritional support at 9 months post-WART; 2 further patients had asymptomatic (G2) osteoporotic fragility fractures of axial skeleton at 12 months post-radiation treated with anti-resorptive agents (denosumab). Conclusions: The clinical utility of intensity-modulated WART in OCCC over-expressing HNF-1β was suggested in this small observational cohort study. The hypothesis that HNF-1β is a portent of platinum-resistance and an important predictive biomarker in OCCC needs further confirmation. Curating multi-institutional cohort studies utilizing WART by means of “Big Data” may improve OCCC care standards in the future.

References Powered by Scopus

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

5703Citations
N/AReaders
Get full text

Ovarian cancer statistics, 2018

2565Citations
N/AReaders
Get full text

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

1058Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Unveiling the Immune Microenvironment’s Role in Breast Cancer: A Glimpse into Promising Frontiers

18Citations
N/AReaders
Get full text

Ovarian Cancer Radiosensitivity: What Have We Understood So Far?

6Citations
N/AReaders
Get full text

Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer?

4Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Stevens, M. J., West, S., Gard, G., Renaud, C., Nevell, D., Roderick, S., & Le, A. (2021). Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature. Radiation Oncology, 16(1). https://doi.org/10.1186/s13014-021-01750-4

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

73%

Researcher 2

18%

Professor / Associate Prof. 1

9%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

50%

Nursing and Health Professions 4

29%

Biochemistry, Genetics and Molecular Bi... 2

14%

Decision Sciences 1

7%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 2

Save time finding and organizing research with Mendeley

Sign up for free